Introduction/Background The objective of our present study was to identify the Clinicopathologic factors that are associated with increased risk of recurrence for borderline ovarian tumors.
Methodology We performed a retrospective review of all cases of BOT treated at our institute from January 2005 to December 2017. Disease free survival (DFS) was calculated from the date of surgery to the date of recurrence or last follow up. Overall survival (OS) was calculated from the date of surgery to date of death or last follow up. The effect of various variables on recurrence was evaluated by univariate and multivariate Cox-proportional hazard method.
Results A total of 75 patients were identified. The median age of patients was 42 years. Abdominal pain was the most common symptom (54.6%). Complete staging was done in 47 patients (62.7%). 64 patients had stage I, 5 had stage II and 6 had stage III disease. 27 patients underwent fertility sparing surgery. Implants were seen in 11 patients, with invasive implants in 6 patients. 7 patients received adjuvant chemotherapy. The median follow up was 53 months (range, 6–165 months). 7 patients developed borderline recurrence and 5 developed invasive recurrence. All the patients with borderline relapses were successfully managed by second surgery. 3 patients with invasive recurrence died of disease. On univariate analysis, the factors significantly associated with worse DFS were Nulliparity (p=0.015), advanced stage (stage Ic and above) (p=0.003), incomplete staging (p=0.006), fertility sparing surgery (p=0.0007) and presence of implants (p=0.026). On multivariate analysis, only incomplete staging (p=0.003) and advanced stage (p=0.02) held significance.
Conclusion Advanced stage and incomplete staging are associated with increased risk of recurrence in borderline ovarian tumors. Borderline relapses are usually managed successfully by second surgery and have good prognosis while invasive relapses are often associated with fatal course.
Disclosure Nothing to disclose
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.